HSIC vs KNSA: fair value comparison
Henry Schein, Inc. and Kiniksa Pharmaceuticals International, plc · Updated 2026-09-12
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, KNSA currently sits closer to the top of our discount ranking. KNSA carries the stronger quality grade.
| HSIC | KNSA | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $88.36 | $79.28 |
| 12-month range | $63.20–$88.52 | $37.47–$79.28 |
| Sector rank | #71 of 113 Healthcare | #69 of 113 Healthcare |
| Quality grade | F | A |
| Leverage | Moderate | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: HSIC fair value analysis · KNSA fair value analysis